$CVS
CVS HEALTH Corp Stock $cvs

$cvs Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000006480324000007 Filed on February 07, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$88.44B	$93.81B	$357.8B
YoY Change	3.7%	11.89%	10.95%
Cost Of Revenue	$75.88B	$79.94B	$217.1B
YoY Change	47.46%	54.53%	10.26%
Gross Profit	$12.56B	$13.88B	$140.7B
YoY Change	-62.86%	-56.8%	12.03%
Gross Profit Margin	14.2%	14.79%	39.32%
Selling, General & Admin			$985.0M
YoY Change			32.21%
% of Gross Profit			0.7%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$1.138B		$4.366B
YoY Change	13.69%		2.8%
% of Gross Profit	9.06%		3.1%
Operating Expenses	$10.29B	$10.02B	$39.35B
YoY Change	-65.73%	-64.72%	-64.07%
Operating Profit	$2.271B	$3.860B	$13.74B
YoY Change	-34.1%	3.51%	77.42%
Interest Expense	-$716.0M	-$690.0M	$2.658B
YoY Change	-221.56%	25.0%	16.22%
% of Operating Profit	-31.53%	-17.88%	19.34%
Other Income/Expense, Net	$25.00M	$22.00M	$88.00M
YoY Change	13.64%	-48.84%	-47.93%
Pretax Income	$1.580B	$2.705B	$11.17B
YoY Change	-45.12%	-12.99%	98.53%
Income Tax	$456.0M	$658.0M	$2.805B
% Of Pretax Income	28.86%	24.33%	25.11%
Net Earnings	$1.113B	$2.046B	$8.344B
YoY Change	-47.89%	-11.12%	101.11%
Net Earnings / Revenue	1.26%	2.18%	2.33%
Basic Earnings Per Share	$0.88		$6.49
Diluted Earnings Per Share	$0.88	$1.58	$6.47
COMMON SHARES
Basic Shares Outstanding	1.258B shares	1.287B shares	1.285B shares
Diluted Shares Outstanding	1.267B shares		1.290B shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$13.09B	$11.46B	$11.46B
YoY Change	-26.13%	-27.14%	-27.14%
Cash & Equivalents	$9.801B	$8.196B	$8.196B
Short-Term Investments	$3.288B	$3.259B	$3.259B
Other Short-Term Assets	$5.821B	$3.151B	$3.151B
YoY Change	54.53%	17.36%	-12.3%
Inventory	$16.35B	$18.03B	$18.03B
Prepaid Expenses
Receivables	$10.59B	$35.23B	$11.91B
Other Receivables	$21.63B	$3.894B	$23.32B
Total Short-Term Assets	$67.47B	$67.86B	$67.86B
YoY Change	-1.79%	3.31%	3.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$30.08B	$30.44B	$30.44B
YoY Change	133.7%	136.43%	-1.79%
Goodwill	$91.27B	$91.27B
YoY Change	8.58%	16.79%
Intangibles	$28.77B	$29.23B
YoY Change	9.11%	18.1%
Long-Term Investments	$24.07B	$23.02B	$23.02B
YoY Change	11.39%	9.12%	9.12%
Other Assets	$8.072B	$4.660B	$7.910B
YoY Change	67.33%	0.87%	4.02%
Total Long-Term Assets	$182.3B	$181.9B	$181.9B
YoY Change	6.83%	11.86%	11.86%
TOTAL ASSETS
Total Short-Term Assets	$67.47B	$67.86B	$67.86B
Total Long-Term Assets	$182.3B	$181.9B	$181.9B
Total Assets	$249.7B	$249.7B	$249.7B
YoY Change	4.35%	9.4%	9.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$50.37B	$49.82B	$49.82B
YoY Change	15.88%	11.54%	11.54%
Accrued Expenses	$24.14B	$22.19B	$23.78B
YoY Change	12.2%	18.37%	16.85%
Deferred Revenue	$117.0M	$149.0M
YoY Change	-13.97%	109.86%
Short-Term Debt	$2.719B	$200.0M	$200.0M
YoY Change
Long-Term Debt Due	$3.731B	$2.772B	$2.772B
YoY Change	109.84%	55.91%	55.91%
Total Short-Term Liabilities	$83.32B	$79.19B	$79.19B
YoY Change	11.01%	13.56%	13.56%
LONG-TERM LIABILITIES
Long-Term Debt	$57.69B	$58.64B	$58.64B
YoY Change	2.2%	16.17%	16.17%
Other Long-Term Liabilities	$30.40B	$6.211B	$30.95B
YoY Change	355.64%	-7.74%	-5.82%
Total Long-Term Liabilities	$88.09B	$6.211B	$89.59B
YoY Change	1220.49%	-7.74%	7.5%
TOTAL LIABILITIES
Total Short-Term Liabilities	$83.32B	$79.19B	$79.19B
Total Long-Term Liabilities	$88.09B	$6.211B	$89.59B
Total Liabilities	$175.8B	$173.1B	$173.3B
YoY Change	4.78%	10.28%	10.18%
SHAREHOLDERS EQUITY
Retained Earnings	$61.87B	$61.60B
YoY Change	7.13%	9.72%
Common Stock	$18.00M	$18.00M
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$73.97B	$76.46B	$76.46B
YoY Change
Total Liabilities & Shareholders Equity	$249.7B	$249.7B	$249.7B
YoY Change	4.35%	9.4%	9.4%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	$1.113B	$2.046B	$8.344B
YoY Change	-47.89%	-11.12%	101.11%
Depreciation, Depletion And Amortization	$1.138B		$4.366B
YoY Change	13.69%		2.8%
Cash From Operating Activities	$4.903B	-$2.636B	$13.43B
YoY Change	-34.08%	35.04%	-17.01%
INVESTING ACTIVITIES
Capital Expenditures	$705.0M	$911.0M	$3.031B
YoY Change	-28.35%	32.41%	11.15%
Acquisitions	$25.00M		$16.61B
YoY Change	-99.65%		11851.08%
Other Investing Activities	-$1.389B	-$331.0M	-$68.00M
YoY Change	4380.65%	-158.17%	-20.0%
Cash From Investing Activities	-$2.094B	-$1.242B	-$20.89B
YoY Change	-75.41%	943.7%	313.89%
FINANCING ACTIVITIES
Cash Dividend Paid	$840.0M		$3.132B
YoY Change	7.83%		7.74%
Common Stock Issuance & Retirement, Net			$2.012B
YoY Change			-42.51%
Debt Paid & Issued, Net	$18.00M		$3.166B
YoY Change	-95.03%		-24.82%
Cash From Financing Activities	-1.227B	-972.0M	$2.683B
YoY Change	-145.01%	-55.56%	-125.51%
NET CHANGE
Cash From Operating Activities	4.903B	-2.636B	$13.43B
Cash From Investing Activities	-2.094B	-1.242B	-$20.89B
Cash From Financing Activities	-1.227B	-972.0M	$2.683B
Net Change In Cash	1.582B	-4.850B	-$4.780B
YoY Change	-4.12%	13.9%	-878.5%
FREE CASH FLOW
Cash From Operating Activities	$4.903B	-$2.636B	$13.43B
Capital Expenditures	$705.0M	$911.0M	$3.031B
Free Cash Flow	$4.198B	-$3.547B	$10.40B
YoY Change	-34.96%	34.36%	-22.71%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Policyholder Benefits And Claims Incurred Health Care PolicyholderBenefitsAndClaimsIncurredHealthCare	71073000000	usd
CY2021	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	88000000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	169000000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	182000000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	11173000000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5836000000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	10537000000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1509000000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2548000000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	7989000000	usd
CY2022	us-gaap	Repayments Of Other Short Term Debt RepaymentsOfOtherShortTermDebt	0	usd
CY2021	us-gaap	Repayments Of Other Short Term Debt RepaymentsOfOtherShortTermDebt	0	usd
CY2023	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	10898000000	usd
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	149000000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	71000000	usd
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	344033000000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	314513000000	usd
CY2021	us-gaap	Interest Expense InterestExpense	2503000000	usd
CY2023	cvs	Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	-3000000	usd
CY2023	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	5031000000	usd
CY2023	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	9000000	usd
CY2022	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	24000000	usd
CY2023	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	420000000	usd
CY2022	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	177000000	usd
CY2021	us-gaap	Debt Securities Available For Sale Realized Loss DebtSecuritiesAvailableForSaleRealizedLoss	14000000	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0000064803
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2021	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2020	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2023#AccountingStandardsUpdate201812Member
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2023Q4	us-gaap	Finance Lease Liability Statement Of Financial Position Extensible List FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations
CY2022Q4	us-gaap	Finance Lease Liability Statement Of Financial Position Extensible List FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-01011
CY2023	dei	Entity Registrant Name EntityRegistrantName	CVS HEALTH CORPORATION
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	05-0494040
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	One CVS Drive,
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Woonsocket,
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	RI
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02895
CY2023	dei	City Area Code CityAreaCode	(401)
CY2023	dei	Local Phone Number LocalPhoneNumber	765-1500
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
CY2023	dei	Trading Symbol TradingSymbol	CVS
CY2023	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	88547881979	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1258449553	shares
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	us-gaap	Premiums Earned Net PremiumsEarnedNet	99192000000	usd
CY2022	us-gaap	Premiums Earned Net PremiumsEarnedNet	85330000000	usd
CY2021	us-gaap	Premiums Earned Net PremiumsEarnedNet	76132000000	usd
CY2023	us-gaap	Net Investment Income NetInvestmentIncome	1153000000	usd
CY2022	us-gaap	Net Investment Income NetInvestmentIncome	838000000	usd
CY2021	us-gaap	Net Investment Income NetInvestmentIncome	1199000000	usd
CY2022	us-gaap	Revenues Revenues	322467000000	usd
CY2021	us-gaap	Revenues Revenues	292111000000	usd
CY2023	us-gaap	Policyholder Benefits And Claims Incurred Health Care PolicyholderBenefitsAndClaimsIncurredHealthCare	86247000000	usd
CY2021	us-gaap	Policyholder Benefits And Claims Incurred Health Care PolicyholderBenefitsAndClaimsIncurredHealthCare	64188000000	usd
CY2023	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	507000000	usd
CY2022	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	0	usd
CY2021	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	0	usd
CY2023	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	usd
CY2022	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-5803000000	usd
CY2023	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	349000000	usd
CY2022	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	2533000000	usd
CY2021	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2023	cvs	Store Impairment Charges StoreImpairmentCharges	0	usd
CY2022	cvs	Store Impairment Charges StoreImpairmentCharges	0	usd
CY2021	cvs	Store Impairment Charges StoreImpairmentCharges	1358000000	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	431000000	usd
CY2023	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	39832000000	usd
CY2022	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	38212000000	usd
CY2021	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	37021000000	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	278801000000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	13743000000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	7954000000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	13310000000	usd
CY2023	us-gaap	Interest Expense InterestExpense	2658000000	usd
CY2022	us-gaap	Interest Expense InterestExpense	2287000000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-452000000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	6.49
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	6.47
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.26
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1285000000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1312000000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1319000000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1290000000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1323000000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1329000000	shares
CY2023	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	2.42
CY2022	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	2.20
CY2021	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	2.00
CY2023	us-gaap	Profit Loss ProfitLoss	8368000000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	4327000000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	7989000000	usd
CY2023	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1090000000	usd
CY2022	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-2317000000	usd
CY2021	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-556000000	usd
CY2023	us-gaap	Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax	-67000000	usd
CY2022	us-gaap	Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax	870000000	usd
CY2021	us-gaap	Oci Liability For Future Policy Benefit Gain Loss After Reclassification Adjustment And Tax OciLiabilityForFuturePolicyBenefitGainLossAfterReclassificationAdjustmentAndTax	255000000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	0	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-7000000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	5000000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	17000000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-26000000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	61000000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	168000000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-20000000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	967000000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1598000000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-314000000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	9335000000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	2729000000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	7675000000	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	24000000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	16000000	usd
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-12000000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	9311000000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	2713000000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	7687000000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8196000000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12945000000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	3259000000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	2778000000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	35227000000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	27276000000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	18025000000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	19090000000	usd
CY2023Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	usd
CY2022Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	908000000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3151000000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2636000000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	67858000000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	65633000000	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	23019000000	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	21096000000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	13183000000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	12873000000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	17252000000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	17872000000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	91272000000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	78150000000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	29234000000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	24803000000	usd
CY2023Q4	us-gaap	Separate Account Assets SeparateAccountAssets	3250000000	usd
CY2022Q4	us-gaap	Separate Account Assets SeparateAccountAssets	3228000000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4660000000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4620000000	usd
CY2023Q4	us-gaap	Assets Assets	249728000000	usd
CY2022Q4	us-gaap	Assets Assets	228275000000	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	14897000000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	14838000000	usd
CY2023Q4	cvs	Pharmacy Claims And Discounts Payable Current PharmacyClaimsAndDiscountsPayableCurrent	22874000000	usd
CY2022Q4	cvs	Pharmacy Claims And Discounts Payable Current PharmacyClaimsAndDiscountsPayableCurrent	19423000000	usd
CY2023Q4	cvs	Liability For Claims And Claims Adjustment Expense And Health Care Organization Accounts Payable To Third Party Payor LiabilityForClaimsAndClaimsAdjustmentExpenseAndHealthCareOrganizationAccountsPayableToThirdPartyPayor	12049000000	usd
CY2022Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	10142000000	usd
CY2023Q4	us-gaap	Other Policyholder Funds OtherPolicyholderFunds	1326000000	usd
CY2022Q4	us-gaap	Other Policyholder Funds OtherPolicyholderFunds	1500000000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	22189000000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	18745000000	usd
CY2023Q4	cvs	Other Insurance Liabilities Current OtherInsuranceLiabilitiesCurrent	1141000000	usd
CY2022Q4	cvs	Other Insurance Liabilities Current OtherInsuranceLiabilitiesCurrent	1089000000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1741000000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1678000000	usd
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	200000000	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	0	usd
CY2023Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	2772000000	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	1778000000	usd
CY2023Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	usd
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	228000000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	79189000000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	69421000000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16034000000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16800000000	usd
CY2023Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	58638000000	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	50476000000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	4311000000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	4016000000	usd
CY2023Q4	us-gaap	Separate Accounts Liability SeparateAccountsLiability	3250000000	usd
CY2022Q4	us-gaap	Separate Accounts Liability SeparateAccountsLiability	3228000000	usd
CY2023Q4	cvs	Other Insurance Liabilities Noncurrent OtherInsuranceLiabilitiesNoncurrent	5459000000	usd
CY2022Q4	cvs	Other Insurance Liabilities Noncurrent OtherInsuranceLiabilitiesNoncurrent	5835000000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6211000000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6730000000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	173092000000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	156506000000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1768000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1288000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1758000000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1300000000	shares
CY2023Q4	us-gaap	Common Stocks Including Additional Paid In Capital CommonStocksIncludingAdditionalPaidInCapital	48992000000	usd
CY2022Q4	us-gaap	Common Stocks Including Additional Paid In Capital CommonStocksIncludingAdditionalPaidInCapital	48193000000	usd
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	480000000	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	458000000	shares
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	33838000000	usd
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	31858000000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	61604000000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	56398000000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-297000000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1264000000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	76461000000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	71469000000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	175000000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	300000000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	76636000000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	71769000000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	249728000000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	228275000000	usd
CY2023	us-gaap	Proceeds From Customers ProceedsFromCustomers	345464000000	usd
CY2022	us-gaap	Proceeds From Customers ProceedsFromCustomers	313662000000	usd
CY2021	us-gaap	Proceeds From Customers ProceedsFromCustomers	284219000000	usd
CY2023	cvs	Payments For Inventory And Prescriptions Dispensed By Retail Network Pharmacies PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies	208848000000	usd
CY2022	cvs	Payments For Inventory And Prescriptions Dispensed By Retail Network Pharmacies PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies	189766000000	usd
CY2021	cvs	Payments For Inventory And Prescriptions Dispensed By Retail Network Pharmacies PaymentsForInventoryAndPrescriptionsDispensedByRetailNetworkPharmacies	165783000000	usd
CY2023	cvs	Payments For Insurance Benefits PaymentsForInsuranceBenefits	84097000000	usd
CY2022	cvs	Payments For Insurance Benefits PaymentsForInsuranceBenefits	69728000000	usd
CY2021	cvs	Payments For Insurance Benefits PaymentsForInsuranceBenefits	63598000000	usd
CY2023	us-gaap	Payments To Suppliers And Employees PaymentsToSuppliersAndEmployees	34735000000	usd
CY2022	us-gaap	Payments To Suppliers And Employees PaymentsToSuppliersAndEmployees	32662000000	usd
CY2021	us-gaap	Payments To Suppliers And Employees PaymentsToSuppliersAndEmployees	31652000000	usd
CY2023	us-gaap	Proceeds From Interest And Dividends Received ProceedsFromInterestAndDividendsReceived	1584000000	usd
CY2022	us-gaap	Proceeds From Interest And Dividends Received ProceedsFromInterestAndDividendsReceived	1026000000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	2418000000	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	3195000000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	16177000000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	18265000000	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	7729000000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	6729000000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	7246000000	usd
CY2023	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	9043000000	usd
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	7746000000	usd
CY2021	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	9963000000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3031000000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2727000000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2520000000	usd
CY2023	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	16612000000	usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	139000000	usd
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	146000000	usd
CY2022	us-gaap	Cash Divested From Deconsolidation CashDivestedFromDeconsolidation	2854000000	usd
CY2023	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	0	usd
CY2022	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	-1249000000	usd
CY2021	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	0	usd
CY2023	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-68000000	usd
CY2022	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-85000000	usd
CY2021	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-122000000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-20889000000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5047000000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5261000000	usd
CY2023	us-gaap	Proceeds From Repayments Of Commercial Paper ProceedsFromRepaymentsOfCommercialPaper	200000000	usd
CY2022	us-gaap	Proceeds From Repayments Of Commercial Paper ProceedsFromRepaymentsOfCommercialPaper	0	usd
CY2021	us-gaap	Proceeds From Repayments Of Commercial Paper ProceedsFromRepaymentsOfCommercialPaper	0	usd
CY2023	us-gaap	Proceeds From Other Short Term Debt ProceedsFromOtherShortTermDebt	5000000000	usd
CY2022	us-gaap	Proceeds From Other Short Term Debt ProceedsFromOtherShortTermDebt	0	usd
CY2021	us-gaap	Proceeds From Other Short Term Debt ProceedsFromOtherShortTermDebt	0	usd
CY2023	us-gaap	Repayments Of Other Short Term Debt RepaymentsOfOtherShortTermDebt	5000000000	usd
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	987000000	usd
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	3166000000	usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	4211000000	usd
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	10254000000	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2012000000	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	3500000000	usd
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	usd
CY2023	us-gaap	Payments Of Dividends PaymentsOfDividends	3132000000	usd
CY2022	us-gaap	Payments Of Dividends PaymentsOfDividends	2907000000	usd
CY2021	us-gaap	Payments Of Dividends PaymentsOfDividends	2625000000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	277000000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	551000000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	549000000	usd
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	181000000	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	370000000	usd
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	168000000	usd
CY2023	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-201000000	usd
CY2022	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-79000000	usd
CY2021	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	155000000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2683000000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-10516000000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-11356000000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4780000000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	614000000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1648000000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13305000000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12691000000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11043000000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8525000000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13305000000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12691000000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	8368000000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	4327000000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	7989000000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4366000000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4224000000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4486000000	usd
CY2023	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	349000000	usd
CY2022	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	2533000000	usd
CY2021	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2023	cvs	Store Impairment Charges StoreImpairmentCharges	0	usd
CY2022	cvs	Store Impairment Charges StoreImpairmentCharges	0	usd
CY2021	cvs	Store Impairment Charges StoreImpairmentCharges	1358000000	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	431000000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	588000000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	447000000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	484000000	usd
CY2023	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
CY2022	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	475000000	usd
CY2021	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-452000000	usd
CY2023	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-676000000	usd
CY2022	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-2029000000	usd
CY2021	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-402000000	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-416000000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-332000000	usd
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	390000000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6260000000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2971000000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2703000000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1233000000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1435000000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-735000000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	510000000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	491000000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	30000000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3618000000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4260000000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2898000000	usd
CY2023	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	394000000	usd
CY2022	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	992000000	usd
CY2021	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	101000000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	1540000000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	6463000000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	2856000000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	13426000000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	16177000000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	18265000000	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	69701000000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	7989000000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-314000000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	864000000	usd
CY2021	cvs	Espp Issuance Net Of Treasury Stock Value Acquired Cost Method ESPPIssuanceNetOfTreasuryStockValueAcquiredCostMethod	5000000	usd
CY2021	us-gaap	Dividends Common Stock DividendsCommonStock	2644000000	usd
CY2021	cvs	Noncontrolling Interest Other Period Increase Decrease NoncontrollingInterestOtherPeriodIncreaseDecrease	6000000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	74841000000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	4327000000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1598000000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	816000000	usd
CY2022	cvs	Treasury Stock Value Acquired Cost Method Net Of Espp Issuance TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance	3685000000	usd
CY2022	us-gaap	Dividends Common Stock DividendsCommonStock	2910000000	usd
CY2022	cvs	Noncontrolling Interest Other Period Increase Decrease NoncontrollingInterestOtherPeriodIncreaseDecrease	-22000000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	71769000000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	8368000000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	967000000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	795000000	usd
CY2023	cvs	Treasury Stock Value Acquired Cost Method Net Of Espp Issuance TreasuryStockValueAcquiredCostMethodNetOfESPPIssuance	1992000000	usd
CY2023	us-gaap	Dividends Common Stock DividendsCommonStock	3138000000	usd
CY2023	us-gaap	Noncontrolling Interest Increase From Business Combination NoncontrollingInterestIncreaseFromBusinessCombination	66000000	usd
CY2023	cvs	Noncontrolling Interest Other Period Increase Decrease NoncontrollingInterestOtherPeriodIncreaseDecrease	-199000000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	76636000000	usd
CY2023Q4	cvs	Treasury Stock Shares Heldin Trust TreasuryStockSharesHeldinTrust	1000000	shares
CY2021Q4	cvs	Treasury Stock Shares Heldin Trust TreasuryStockSharesHeldinTrust	1000000	shares
CY2022Q4	cvs	Treasury Stock Shares Heldin Trust TreasuryStockSharesHeldinTrust	1000000	shares
CY2021Q4	cvs	Treasury Stock Value Shares Held In Trust TreasuryStockValueSharesHeldInTrust	29000000	usd
CY2023Q4	cvs	Treasury Stock Value Shares Held In Trust TreasuryStockValueSharesHeldInTrust	29000000	usd
CY2022Q4	cvs	Treasury Stock Value Shares Held In Trust TreasuryStockValueSharesHeldInTrust	29000000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	18000000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	18000000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	17000000	usd
CY2023Q4	cvs	Number Of Pharmacy Plan Members NumberOfPharmacyPlanMembers	108000000	people
CY2023Q4	cvs	Number Of Patients Served Per Year NumberOfPatientsServedPerYear	1000000	patient
CY2023	us-gaap	Number Of Businesses Acquired NumberOfBusinessesAcquired	2	business
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	4	segment
CY2023	us-gaap	Number Of Businesses Acquired NumberOfBusinessesAcquired	2	business
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div>The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8196000000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12945000000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9408000000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	90000000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	144000000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	3065000000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	239000000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	216000000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	218000000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8525000000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13305000000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12691000000	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	11908000000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	8983000000	usd
CY2023Q4	cvs	Vendorand Manufacturer Receivables VendorandManufacturerReceivables	15711000000	usd
CY2022Q4	cvs	Vendorand Manufacturer Receivables VendorandManufacturerReceivables	12395000000	usd
CY2023Q4	us-gaap	Premiums Receivable At Carrying Value PremiumsReceivableAtCarryingValue	3714000000	usd
CY2022Q4	us-gaap	Premiums Receivable At Carrying Value PremiumsReceivableAtCarryingValue	2676000000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	3894000000	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	3449000000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	35227000000	usd
CY2022Q4	cvs	Accounts Receivable After Allowance For Credit Loss Current Including Assets Held For Sale AccountsReceivableAfterAllowanceForCreditLossCurrentIncludingAssetsHeldForSale	27503000000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	343000000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	333000000	usd
CY2022Q4	us-gaap	Deferred Policy Acquisition Costs DeferredPolicyAcquisitionCosts	1219000000	usd
CY2021Q4	us-gaap	Deferred Policy Acquisition Costs DeferredPolicyAcquisitionCosts	879000000	usd
CY2023	us-gaap	Deferred Policy Acquisition Costs Additions DeferredPolicyAcquisitionCostsAdditions	548000000	usd
CY2022	us-gaap	Deferred Policy Acquisition Costs Additions DeferredPolicyAcquisitionCostsAdditions	564000000	usd
CY2023	us-gaap	Deferred Policy Acquisition Cost Amortization Expense DeferredPolicyAcquisitionCostAmortizationExpense	265000000	usd
CY2022	us-gaap	Deferred Policy Acquisition Cost Amortization Expense DeferredPolicyAcquisitionCostAmortizationExpense	224000000	usd
CY2023Q4	us-gaap	Deferred Policy Acquisition Costs DeferredPolicyAcquisitionCosts	1502000000	usd
CY2022Q4	us-gaap	Deferred Policy Acquisition Costs DeferredPolicyAcquisitionCosts	1219000000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	33882000000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	34600000000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	20699000000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	21483000000	usd
CY2023Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	13183000000	usd
CY2022Q4	cvs	Property Plant And Equipment Net Including Assets Held For Sale PropertyPlantAndEquipmentNetIncludingAssetsHeldForSale	13117000000	usd
CY2023	us-gaap	Depreciation Depreciation	2500000000	usd
CY2022	us-gaap	Depreciation Depreciation	2400000000	usd
CY2021	us-gaap	Depreciation Depreciation	2300000000	usd
CY2023	cvs	Office Real Estate Optimization Charges OfficeRealEstateOptimizationCharges	46000000	usd
CY2022	cvs	Office Real Estate Optimization Charges OfficeRealEstateOptimizationCharges	117000000	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
CY2023	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
CY2021	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
CY2023Q4	cvs	Premium Deficiency Reserve Liability PremiumDeficiencyReserveLiability	0	usd
CY2022Q4	cvs	Premium Deficiency Reserve Liability PremiumDeficiencyReserveLiability	0	usd
CY2023	us-gaap	Allocations To Policyholders Policies AllocationsToPolicyholdersPolicies	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Policyholders’ Funds</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Policyholders’ funds consist primarily of reserves for pension and annuity investment contracts and customer funds associated with certain health contracts. Reserves for such contracts are equal to cumulative deposits less withdrawals and charges plus interest credited thereon, net of experience-rated adjustments. Reserves for contracts subject to experience rating reflect the Company’s rights as well as the rights of policyholders and plan participants.</span></div>Policyholders’ funds liabilities that are expected to be paid within twelve months from the balance sheet date are classified as current on the consolidated balance sheets. Policyholders’ funds liabilities that are expected to be paid greater than twelve months from the balance sheet date are included in other long-term liabilities on the consolidated balance sheets.
CY2023Q4	us-gaap	Self Insurance Reserve SelfInsuranceReserve	1100000000	usd
CY2022Q4	us-gaap	Self Insurance Reserve SelfInsuranceReserve	1100000000	usd
CY2023Q4	cvs	Affordable Care Act Risk Adjustment Payable AffordableCareActRiskAdjustmentPayable	1200000000	usd
CY2022Q4	cvs	Affordable Care Act Risk Adjustment Payable AffordableCareActRiskAdjustmentPayable	0	usd
CY2023	us-gaap	Net Investment Income NetInvestmentIncome	1153000000	usd
CY2023	us-gaap	Revenues Revenues	357776000000	usd
CY2022	us-gaap	Net Investment Income NetInvestmentIncome	838000000	usd
CY2022	us-gaap	Revenues Revenues	322467000000	usd
CY2021	us-gaap	Net Investment Income NetInvestmentIncome	1199000000	usd
CY2021	us-gaap	Revenues Revenues	292111000000	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	11908000000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	8983000000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	71000000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	87000000	usd
CY2023	cvs	Contract With Customer Liability Loyalty Program Earnings And Gift Card Issuance ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance	357000000	usd
CY2022	cvs	Contract With Customer Liability Loyalty Program Earnings And Gift Card Issuance ContractWithCustomerLiabilityLoyaltyProgramEarningsAndGiftCardIssuance	340000000	usd
CY2023	cvs	Contract With Customer Liability Redemption And Breakage ContractWithCustomerLiabilityRedemptionAndBreakage	363000000	usd
CY2022	cvs	Contract With Customer Liability Redemption And Breakage ContractWithCustomerLiabilityRedemptionAndBreakage	356000000	usd
CY2023	us-gaap	Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination	109000000	usd
CY2022	us-gaap	Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination	0	usd
CY2023	cvs	Contract With Customer Liability Other Increase Decrease ContractWithCustomerLiabilityOtherIncreaseDecrease	-25000000	usd
CY2022	cvs	Contract With Customer Liability Other Increase Decrease ContractWithCustomerLiabilityOtherIncreaseDecrease	0	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	149000000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	71000000	usd
CY2023	cvs	Pharmacy Rebate Period PharmacyRebatePeriod	P30D
CY2023	us-gaap	Advertising Expense AdvertisingExpense	985000000	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	745000000	usd
CY2021	us-gaap	Advertising Expense AdvertisingExpense	707000000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5836000000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1509000000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	4327000000	usd
CY2023Q4	cvs	Treasury Stock Shares Heldin Trust TreasuryStockSharesHeldinTrust	1000000	shares
CY2022Q4	cvs	Treasury Stock Shares Heldin Trust TreasuryStockSharesHeldinTrust	1000000	shares
CY2022	cvs	Related Party Transaction Charitable Contribution To Non Profit Entity RelatedPartyTransactionCharitableContributionToNonProfitEntity	25000000	usd
CY2021	cvs	Related Party Transaction Charitable Contribution To Non Profit Entity RelatedPartyTransactionCharitableContributionToNonProfitEntity	50000000	usd
CY2023	cvs	Related Party Transaction Charitable Contribution To Non Profit Entity RelatedPartyTransactionCharitableContributionToNonProfitEntity	0	usd
CY2022	us-gaap	Policyholder Benefits And Claims Incurred Health Care PolicyholderBenefitsAndClaimsIncurredHealthCare	71073000000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	314513000000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	7954000000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	4311000000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.29
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.26
CY2021	us-gaap	Policyholder Benefits And Claims Incurred Health Care PolicyholderBenefitsAndClaimsIncurredHealthCare	64188000000	usd
CY2021	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	37021000000	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	278801000000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	13310000000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	10537000000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2548000000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	7989000000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	8001000000	usd
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	6.07
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	6.02
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2636000000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	65633000000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	24803000000	usd
CY2022Q4	us-gaap	Assets Assets	228275000000	usd
CY2022Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	10142000000	usd
CY2022Q4	cvs	Other Insurance Liabilities Current OtherInsuranceLiabilitiesCurrent	1089000000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	69421000000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	4016000000	usd
CY2022Q4	cvs	Other Insurance Liabilities Noncurrent OtherInsuranceLiabilitiesNoncurrent	5835000000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6730000000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	156506000000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	56398000000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1264000000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	71469000000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	71769000000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	228275000000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	4327000000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4224000000	usd
CY2022	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-2029000000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	491000000	usd
CY2022	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	992000000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	6463000000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	7989000000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4486000000	usd
CY2021	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-402000000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	30000000	usd
CY2021	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	101000000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	2856000000	usd
CY2023Q2	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	5000000000	usd
CY2023Q1	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	6000000000	usd
CY2023	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	507000000	usd
CY2023	us-gaap	Severance Costs1 SeveranceCosts1	344000000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	152000000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	11000000	usd
CY2022Q4	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	0	usd
CY2023	us-gaap	Severance Costs1 SeveranceCosts1	344000000	usd
CY2023	us-gaap	Payments For Postemployment Benefits PaymentsForPostemploymentBenefits	194000000	usd
CY2023Q4	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	150000000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	3259000000	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	23019000000	usd
CY2023Q4	us-gaap	Investments Investments	26278000000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	2778000000	usd
CY2022Q4	cvs	Long Term Investments Including Assets Held For Sale LongTermInvestmentsIncludingAssetsHeldForSale	21113000000	usd
CY2022Q4	us-gaap	Investments Investments	23891000000	usd
CY2023Q4	us-gaap	Restricted Investments At Fair Value RestrictedInvestmentsAtFairValue	307000000	usd
CY2022Q4	us-gaap	Restricted Investments At Fair Value RestrictedInvestmentsAtFairValue	331000000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	22282000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss	22282000000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	267000000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	836000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	21713000000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	22067000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	4000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss	22063000000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	57000000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1840000000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	20280000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	1244000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	1230000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	7563000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	7390000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost	4302000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	4204000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost	3951000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Maturities After Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue	3802000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostAfterAllowanceForCreditLoss	22282000000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	21713000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	1182	security
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	1932000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	28000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	7018	security
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	10616000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	808000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	8200	security
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	12548000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	836000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions	9500	security
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	14228000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	1226000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions	2784	security
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	4264000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	614000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	12284	security
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	18492000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	1840000000	usd
CY2023Q4	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date Within One Year DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYear	1072000000	usd
CY2023Q4	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date Within One Year Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateWithinOneYearAccumulatedLoss	16000000	usd
CY2023Q4	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After One Through Five Years DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYears	4632000000	usd
CY2023Q4	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After One Through Five Years Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterOneThroughFiveYearsAccumulatedLoss	229000000	usd
CY2023Q4	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Five Through Ten Years DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYears	2012000000	usd
CY2023Q4	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Five Through Ten Years Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterFiveThroughTenYearsAccumulatedLoss	179000000	usd
CY2023Q4	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Ten Years DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYears	2227000000	usd
CY2023Q4	cvs	Debt Securities Available For Sale Continuous Unrealized Loss Position Allocated And Single Maturity Date After Ten Years Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionAllocatedAndSingleMaturityDateAfterTenYearsAccumulatedLoss	234000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	12548000000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	836000000	usd
CY2021	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	72000000	usd
CY2023	us-gaap	Fair Value Asset Recurring Basis Still Held Unrealized Gain Loss Oci FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci	-9000000	usd
CY2022	us-gaap	Fair Value Asset Recurring Basis Still Held Unrealized Gain Loss Oci FairValueAssetRecurringBasisStillHeldUnrealizedGainLossOci	-9000000	usd
CY2023	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	1696000000	usd
CY2022	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	1201000000	usd
CY2021	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	1070000000	usd
CY2023	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	46000000	usd
CY2022	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	43000000	usd
CY2021	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	47000000	usd
CY2023	cvs	Investment Income Excluding Capital Gains Or Losses InvestmentIncomeExcludingCapitalGainsOrLosses	1650000000	usd
CY2022	cvs	Investment Income Excluding Capital Gains Or Losses InvestmentIncomeExcludingCapitalGainsOrLosses	1158000000	usd
CY2021	cvs	Investment Income Excluding Capital Gains Or Losses InvestmentIncomeExcludingCapitalGainsOrLosses	1023000000	usd
CY2023	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-497000000	usd
CY2022	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-320000000	usd
CY2021	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	176000000	usd
CY2023	us-gaap	Investment Income Net InvestmentIncomeNet	1153000000	usd
CY2022	us-gaap	Investment Income Net InvestmentIncomeNet	838000000	usd
CY2021	us-gaap	Investment Income Net InvestmentIncomeNet	1199000000	usd
CY2023	cvs	Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	152000000	usd
CY2022	cvs	Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	143000000	usd
CY2022	cvs	Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	13000000	usd
CY2021	cvs	Yield Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings YieldRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	42000000	usd
CY2021	cvs	Credit Related Impairment Loss Debt Securities Available For Sale Recognized In Earnings CreditRelatedImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	0	usd
CY2022	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	4243000000	usd
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	3572000000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	2532000000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	2579000000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	2633000000	usd
CY2023	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	84000000	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	79000000	usd
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	62000000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	79121000000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	78150000000	usd
CY2023	us-gaap	Goodwill Transfers GoodwillTransfers	0	usd
CY2023	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	13122000000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	91272000000	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	6600000000	usd
CY2022Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	6600000000	usd
CY2023Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	10498000000	usd
CY2023Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	10498000000	usd
CY2023Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	44166000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	14932000000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	29234000000	usd
CY2023	us-gaap	Finite Lived Intangible Asset Weighted Average Period Before Next Renewal Or Extension FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension	P14Y6M
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	10498000000	usd
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	10498000000	usd
CY2022Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	37859000000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	13028000000	usd
CY2022Q4	cvs	Intangible Assets Net Excluding Goodwill Including Assets Held For Sale IntangibleAssetsNetExcludingGoodwillIncludingAssetsHeldForSale	24831000000	usd
CY2022	us-gaap	Finite Lived Intangible Asset Weighted Average Period Before Next Renewal Or Extension FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension	P13Y10M24D
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1900000000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1800000000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2200000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2011000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1964000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1687000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1580000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1306000000	usd
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	73000000	usd
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	68000000	usd
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	62000000	usd
CY2023	cvs	Finance Lease Cost FinanceLeaseCost	157000000	usd
CY2022	cvs	Finance Lease Cost FinanceLeaseCost	147000000	usd
CY2021	cvs	Finance Lease Cost FinanceLeaseCost	124000000	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	22000000	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	27000000	usd
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	25000000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	635000000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	610000000	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	604000000	usd
CY2023	us-gaap	Sublease Income SubleaseIncome	63000000	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	61000000	usd
CY2021	us-gaap	Sublease Income SubleaseIncome	59000000	usd
CY2023	us-gaap	Lease Cost LeaseCost	3283000000	usd
CY2022	us-gaap	Lease Cost LeaseCost	3302000000	usd
CY2021	us-gaap	Lease Cost LeaseCost	3327000000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	2756000000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	2689000000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	2714000000	usd
CY2023	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	73000000	usd
CY2022	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	68000000	usd
CY2021	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	62000000	usd
CY2023	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	70000000	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	62000000	usd
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	50000000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1132000000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	591000000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1254000000	usd
CY2023	cvs	Right Of Use Asset Obtained Reduced In Exchange For Finance Lease Liability RightOfUseAssetObtainedReducedInExchangeForFinanceLeaseLiability	-4000000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	232000000	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	278000000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	17252000000	usd
CY2022Q4	cvs	Operating Lease Right Of Use Asset Including Assets Held For Sale OperatingLeaseRightOfUseAssetIncludingAssetsHeldForSale	17928000000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1741000000	usd
CY2022Q4	cvs	Operating Lease Liability Current Including Liabilities Held For Sale OperatingLeaseLiabilityCurrentIncludingLiabilitiesHeldForSale	1699000000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	16034000000	usd
CY2022Q4	cvs	Operating Lease Liability Noncurrent Including Liabilities Held For Sale OperatingLeaseLiabilityNoncurrentIncludingLiabilitiesHeldForSale	16839000000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	17775000000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	18538000000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	1604000000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Before Accumulated Amortization FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization	1608000000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	375000000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset Accumulated Amortization FinanceLeaseRightOfUseAssetAccumulatedAmortization	284000000	usd
CY2023Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	1229000000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	1324000000	usd
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	66000000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	59000000	usd
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	1325000000	usd
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	1406000000	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	1391000000	usd
CY2022Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	1465000000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P11Y4M24D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P12Y2M12D
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P17Y3M18D
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P19Y4M24D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.045
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.044
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.050
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.049
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	143000000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2716000000	usd
CY2023Q4	cvs	Lessee Liability Payments Year One LesseeLiabilityPaymentsYearOne	2859000000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	138000000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2559000000	usd
CY2023Q4	cvs	Lessee Liability Payments Due Year Two LesseeLiabilityPaymentsDueYearTwo	2697000000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	130000000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2369000000	usd
CY2023Q4	cvs	Lessee Liability Payments Due Year Three LesseeLiabilityPaymentsDueYearThree	2499000000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	127000000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2181000000	usd
CY2023Q4	cvs	Lessee Liability Payments Due Year Four LesseeLiabilityPaymentsDueYearFour	2308000000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Five FinanceLeaseLiabilityPaymentsDueYearFive	124000000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2024000000	usd
CY2023Q4	cvs	Lessee Liability Payments Due Year Five LesseeLiabilityPaymentsDueYearFive	2148000000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due After Year Five FinanceLeaseLiabilityPaymentsDueAfterYearFive	1446000000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	11004000000	usd
CY2023Q4	cvs	Lessee Liability Payments Due After Year Five LesseeLiabilityPaymentsDueAfterYearFive	12450000000	usd
CY2023Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	2108000000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	22853000000	usd
CY2023Q4	cvs	Lessee Liability Payments Due LesseeLiabilityPaymentsDue	24961000000	usd
CY2023Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	717000000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5078000000	usd
CY2023Q4	cvs	Lessee Liability Undiscounted Excess Amount LesseeLiabilityUndiscountedExcessAmount	5795000000	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	1391000000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	17775000000	usd
CY2023Q4	cvs	Lease Liability LeaseLiability	19166000000	usd
CY2023Q4	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	289000000	usd
CY2023Q4	cvs	Operating And Capital Leases Amount Due In Excess Of Remaining Estimated Economic Life OperatingAndCapitalLeasesAmountDueInExcessOfRemainingEstimatedEconomicLife	2100000000	usd
CY2022Q4	cvs	Office Real Estate Optimization Charges OfficeRealEstateOptimizationCharges	117000000	usd
CY2023	cvs	Office Real Estate Optimization Charges OfficeRealEstateOptimizationCharges	46000000	usd
CY2023	us-gaap	Interest Credited To Policyholders Account Balances InterestCreditedToPolicyholdersAccountBalances	9000000	usd
CY2023	us-gaap	Policyholder Account Balance Policy Charge PolicyholderAccountBalancePolicyCharge	2000000	usd
CY2022	us-gaap	Policyholder Account Balance Policy Charge PolicyholderAccountBalancePolicyCharge	2000000	usd
CY2023	us-gaap	Policyholder Account Balance Surrender And Withdrawal PolicyholderAccountBalanceSurrenderAndWithdrawal	35000000	usd
CY2022	us-gaap	Policyholder Account Balance Surrender And Withdrawal PolicyholderAccountBalanceSurrenderAndWithdrawal	31000000	usd
CY2023	us-gaap	Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the December 31, 2023 health care net incurred and paid claims development tables to the health care costs payable liability on the consolidated balance sheet were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.105%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">In millions</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-duration health care costs payable, net of reinsurance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,535 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reinsurance recoverables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance lines other than short duration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-insurance health care costs payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total health care costs payable</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,049 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>
CY2023Q4	us-gaap	Health Care Organization Accounts Payable To Third Party Payor HealthCareOrganizationAccountsPayableToThirdPartyPayor	1292000000	usd
CY2023Q4	cvs	Liability For Claims And Claims Adjustment Expense And Health Care Organization Accounts Payable To Third Party Payor LiabilityForClaimsAndClaimsAdjustmentExpenseAndHealthCareOrganizationAccountsPayableToThirdPartyPayor	12049000000	usd
CY2023	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Business Acquisitions LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions	1098000000	usd
CY2023	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	86639000000	usd
CY2023	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-685000000	usd
CY2023	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	85954000000	usd
CY2023	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	75529000000	usd
CY2023	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	9585000000	usd
CY2023	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	85114000000	usd
CY2023Q4	cvs	Premium Deficiency Reserve Liability PremiumDeficiencyReserveLiability	0	usd
CY2022Q4	cvs	Premium Deficiency Reserve Liability PremiumDeficiencyReserveLiability	0	usd
CY2023Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Net LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet	12067000000	usd
CY2023Q4	us-gaap	Reinsurance Recoverable For Unpaid Claims And Claims Adjustments ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments	5000000	usd
CY2023Q4	us-gaap	Aoci Liability For Future Policy Benefit Expected Future Policy Benefit Before Tax AociLiabilityForFuturePolicyBenefitExpectedFuturePolicyBenefitBeforeTax	23000000	usd
CY2023Q4	cvs	Liability For Claims And Claims Adjustment Expense And Health Care Organization Accounts Payable To Third Party Payor LiabilityForClaimsAndClaimsAdjustmentExpenseAndHealthCareOrganizationAccountsPayableToThirdPartyPayor	12049000000	usd
CY2023	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-685000000	usd
CY2022Q4	us-gaap	Policyholder Funds PolicyholderFunds	345000000	usd
CY2021Q4	us-gaap	Policyholder Funds PolicyholderFunds	522000000	usd
CY2023	cvs	Policyholder Account Balance Deposits Received PolicyholderAccountBalanceDepositsReceived	0	usd
CY2022	cvs	Policyholder Account Balance Deposits Received PolicyholderAccountBalanceDepositsReceived	13000000	usd
CY2022	us-gaap	Interest Credited To Policyholders Account Balances InterestCreditedToPolicyholdersAccountBalances	11000000	usd
CY2023	cvs	Policyholder Account Balance Change In Net Unrealized Gains Losses PolicyholderAccountBalanceChangeInNetUnrealizedGainsLosses	39000000	usd
CY2022	cvs	Policyholder Account Balance Change In Net Unrealized Gains Losses PolicyholderAccountBalanceChangeInNetUnrealizedGainsLosses	-148000000	usd
CY2023	us-gaap	Policyholder Account Balance Increase Decrease From Other Change PolicyholderAccountBalanceIncreaseDecreaseFromOtherChange	-24000000	usd
CY2022	us-gaap	Policyholder Account Balance Increase Decrease From Other Change PolicyholderAccountBalanceIncreaseDecreaseFromOtherChange	-20000000	usd
CY2023Q4	us-gaap	Policyholder Funds PolicyholderFunds	332000000	usd
CY2022Q4	us-gaap	Policyholder Funds PolicyholderFunds	345000000	usd
CY2023Q4	us-gaap	Policyholder Account Balance Weighted Average Crediting Rate PolicyholderAccountBalanceWeightedAverageCreditingRate	0.0432
CY2022Q4	us-gaap	Policyholder Account Balance Weighted Average Crediting Rate PolicyholderAccountBalanceWeightedAverageCreditingRate	0.0472
CY2023Q4	us-gaap	Policyholder Account Balance Net Amount At Risk PolicyholderAccountBalanceNetAmountAtRisk	0	usd
CY2022Q4	us-gaap	Policyholder Account Balance Net Amount At Risk PolicyholderAccountBalanceNetAmountAtRisk	0	usd
CY2023Q4	us-gaap	Cash Surrender Value Due Policyholders Amount CashSurrenderValueDuePolicyholdersAmount	313000000	usd
CY2022Q4	us-gaap	Cash Surrender Value Due Policyholders Amount CashSurrenderValueDuePolicyholdersAmount	339000000	usd
CY2022Q4	us-gaap	Separate Accounts Liability SeparateAccountsLiability	3228000000	usd
CY2021Q4	us-gaap	Separate Accounts Liability SeparateAccountsLiability	5087000000	usd
CY2023	us-gaap	Separate Account Liability Premium And Deposit SeparateAccountLiabilityPremiumAndDeposit	860000000	usd
CY2022	us-gaap	Separate Account Liability Premium And Deposit SeparateAccountLiabilityPremiumAndDeposit	853000000	usd
CY2023	us-gaap	Separate Account Liability Surrender And Withdrawal SeparateAccountLiabilitySurrenderAndWithdrawal	9000000	usd
CY2022	us-gaap	Separate Account Liability Surrender And Withdrawal SeparateAccountLiabilitySurrenderAndWithdrawal	581000000	usd
CY2023	us-gaap	Separate Account Liability Benefit Payment SeparateAccountLiabilityBenefitPayment	938000000	usd
CY2022	us-gaap	Separate Account Liability Benefit Payment SeparateAccountLiabilityBenefitPayment	947000000	usd
CY2023	us-gaap	Separate Account Liability Increase Decrease From Invested Performance SeparateAccountLiabilityIncreaseDecreaseFromInvestedPerformance	100000000	usd
CY2022	us-gaap	Separate Account Liability Increase Decrease From Invested Performance SeparateAccountLiabilityIncreaseDecreaseFromInvestedPerformance	-1130000000	usd
CY2023	us-gaap	Transfer To From Policyholder Account Balance To From Separate Account TransferToFromPolicyholderAccountBalanceToFromSeparateAccount	-7000000	usd
CY2022	us-gaap	Transfer To From Policyholder Account Balance To From Separate Account TransferToFromPolicyholderAccountBalanceToFromSeparateAccount	-9000000	usd
CY2023	us-gaap	Separate Account Liability Increase Decrease From Other Change SeparateAccountLiabilityIncreaseDecreaseFromOtherChange	2000000	usd
CY2022	us-gaap	Separate Account Liability Increase Decrease From Other Change SeparateAccountLiabilityIncreaseDecreaseFromOtherChange	-63000000	usd
CY2023Q4	us-gaap	Separate Accounts Liability SeparateAccountsLiability	3250000000	usd
CY2022Q4	us-gaap	Separate Accounts Liability SeparateAccountsLiability	3228000000	usd
CY2023Q4	us-gaap	Separate Account Liability Cash Surrender Value Amount SeparateAccountLiabilityCashSurrenderValueAmount	2181000000	usd
CY2022Q4	us-gaap	Separate Account Liability Cash Surrender Value Amount SeparateAccountLiabilityCashSurrenderValueAmount	2087000000	usd
CY2023Q4	us-gaap	Commercial Paper CommercialPaper	200000000	usd
CY2022Q4	us-gaap	Commercial Paper CommercialPaper	0	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	1391000000	usd
CY2022Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	1465000000	usd
CY2023Q4	cvs	Short Term Debt Long Term Debt Gross And Lease Obligation ShortTermDebtLongTermDebtGrossAndLeaseObligation	62160000000	usd
CY2022Q4	cvs	Short Term Debt Long Term Debt Gross And Lease Obligation ShortTermDebtLongTermDebtGrossAndLeaseObligation	52753000000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Premium DebtInstrumentUnamortizedPremium	186000000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Premium DebtInstrumentUnamortizedPremium	200000000	usd
CY2023Q4	cvs	Debt Instrument Unamortized Discount And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet	736000000	usd
CY2022Q4	cvs	Debt Instrument Unamortized Discount And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountAndDebtIssuanceCostsNet	696000000	usd
CY2023Q4	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	61610000000	usd
CY2022Q4	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	52257000000	usd
CY2023Q4	us-gaap	Commercial Paper CommercialPaper	200000000	usd
CY2022Q4	us-gaap	Commercial Paper CommercialPaper	0	usd
CY2023Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	2772000000	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	1778000000	usd
CY2023Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	58638000000	usd
CY2022Q4	cvs	Long Term Debt And Lease Obligation Including Liabilities Held For Sale LongTermDebtAndLeaseObligationIncludingLiabilitiesHeldForSale	50479000000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	2705000000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	3785000000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	4008000000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	3379000000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	5007000000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	41685000000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	60569000000	usd
CY2023Q4	us-gaap	Commercial Paper CommercialPaper	200000000	usd
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	1391000000	usd
CY2023Q4	cvs	Short Term Debt Long Term Debt Gross And Lease Obligation ShortTermDebtLongTermDebtGrossAndLeaseObligation	62160000000	usd
CY2023Q4	us-gaap	Federal Home Loan Bank Advances General Debt Obligations Disclosures Maximum Amount Available FederalHomeLoanBankAdvancesGeneralDebtObligationsDisclosuresMaximumAmountAvailable	1000000000	usd
CY2023Q2	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	4900000000	usd
CY2023Q1	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	6000000000	usd
CY2021Q4	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-80000000	usd
CY2021Q4	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	8000000	usd
CY2021Q4	cvs	Debt Extinguishment Fees DebtExtinguishmentFees	1000000	usd
CY2021Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-89000000	usd
CY2021Q3	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-332000000	usd
CY2021Q3	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	26000000	usd
CY2021Q3	cvs	Debt Extinguishment Fees DebtExtinguishmentFees	5000000	usd
CY2021Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-363000000	usd
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	581000000	usd
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	567000000	usd
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	552000000	usd
CY2021	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Expected Long Term Return On Assets DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets	0.048
CY2023Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate	0.050
CY2022Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate	0.052
CY2023	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate	0.051
CY2022	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate	0.023
CY2021	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate	0.018
CY2023	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Expected Long Term Return On Assets DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets	0.063
CY2022	us-gaap	Defined Benefit Plan Assumptions Used Calculating Net Periodic Benefit Cost Expected Long Term Return On Assets DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets	0.048
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	2819000000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	2803000000	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	2285000000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	662000000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	735000000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	665000000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3481000000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3538000000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2950000000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-537000000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-1526000000	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-282000000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-139000000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-503000000	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-120000000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-676000000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2029000000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-402000000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2805000000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1509000000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2548000000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.037
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.032
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.041
CY2023	cvs	Effective Income Tax Rate Reconciliation Nondeductible Expense Legal Charges Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent	0
CY2022	cvs	Effective Income Tax Rate Reconciliation Nondeductible Expense Legal Charges Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent	0.034
CY2021	cvs	Effective Income Tax Rate Reconciliation Nondeductible Expense Legal Charges Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseLegalChargesPercent	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Disposition Of Business EffectiveIncomeTaxRateReconciliationDispositionOfBusiness	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Disposition Of Business EffectiveIncomeTaxRateReconciliationDispositionOfBusiness	0.016
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Disposition Of Business EffectiveIncomeTaxRateReconciliationDispositionOfBusiness	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements Domestic EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements Domestic EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic	-0.026
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements Domestic EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic	-0.012
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.004
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.007
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.003
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.251
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.259
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.242
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	5059000000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	5242000000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Legal Settlements DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements	1205000000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Legal Settlements DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements	1260000000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	94000000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	103000000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	168000000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	153000000	usd
CY2023Q4	cvs	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Bad Debts And Other Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances	606000000	usd
CY2022Q4	cvs	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Bad Debts And Other Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsBadDebtsAndOtherAllowances	480000000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	409000000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	266000000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	62000000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	66000000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	356000000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	319000000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	56000000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	293000000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	372000000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	335000000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	385000000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	532000000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	8002000000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	7985000000	usd
CY2023Q4	cvs	Deferred Tax Liabilities Retirement Benefits DeferredTaxLiabilitiesRetirementBenefits	112000000	usd
CY2022Q4	cvs	Deferred Tax Liabilities Retirement Benefits DeferredTaxLiabilitiesRetirementBenefits	92000000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	4469000000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	4639000000	usd
CY2023Q4	cvs	Deferred Tax Liabilities Depreciation And Amortization DeferredTaxLiabilitiesDepreciationAndAmortization	7732000000	usd
CY2022Q4	cvs	Deferred Tax Liabilities Depreciation And Amortization DeferredTaxLiabilitiesDepreciationAndAmortization	7139000000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	12313000000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	11870000000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	4311000000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	3885000000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	385000000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	532000000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	409000000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	446000000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	782000000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	768000000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2000000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	5000000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	3000000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	46000000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	42000000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	52000000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	24000000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	166000000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	33000000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	34000000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	4000000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	1000000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	213000000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	7000000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	436000000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	446000000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	782000000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	31000000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	29000000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	40000000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	134000000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	112000000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	330000000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	588000000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	447000000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	484000000	usd
CY2023	cvs	Share Based Compensation Arrangement By Share Based Payment Award Shares Common Stock Received Per Restricted Stock Unit Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCommonStockReceivedPerRestrictedStockUnitGranted	1	shares
CY2023	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	3000000	shares
CY2023	cvs	Stock Issued During Period Employee Stock Purchase Plan Average Purchase Priceof Shares Purchased StockIssuedDuringPeriodEmployeeStockPurchasePlanAveragePurchasePriceofSharesPurchased	70.99
CY2021	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	0	shares
CY2023Q1	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	0.605
CY2023Q3	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	0.605
CY2023Q4	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	0.605
CY2023Q2	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	0.605
CY2022Q4	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	0.55
CY2022Q1	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	0.55
CY2022Q2	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	0.55
CY2022Q3	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	0.55
CY2023Q4	cvs	Dividends Payable Quarterly Dividends Declared Increase Amount Percent DividendsPayableQuarterlyDividendsDeclaredIncreaseAmountPercent	0.10
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	6.07
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	6.47
CY2023Q4	us-gaap	Statutory Accounting Practices Statutory Capital And Surplus Required StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired	9011000000	usd
CY2023Q4	us-gaap	Assets Held By Insurance Regulators AssetsHeldByInsuranceRegulators	684000000	usd
CY2023Q4	us-gaap	Statutory Accounting Practices Statutory Amount Available For Dividend Payments Without Regulatory Approval StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval	3098000000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	175000000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	300000000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	967000000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1598000000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-314000000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	8344000000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	8344000000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	4311000000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	4311000000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	8001000000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	8001000000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1285000000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1312000000	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1319000000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1290000000	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1323000000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1329000000	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	6.49
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.29
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.26
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	6.02
CY2023Q4	us-gaap	Reinsurance Recoverables On Paid And Unpaid Losses ReinsuranceRecoverablesOnPaidAndUnpaidLosses	1998000000	usd
CY2022Q4	us-gaap	Reinsurance Recoverables On Paid And Unpaid Losses ReinsuranceRecoverablesOnPaidAndUnpaidLosses	2250000000	usd
CY2023	us-gaap	Direct Premiums Earned DirectPremiumsEarned	99753000000	usd
CY2022	us-gaap	Direct Premiums Earned DirectPremiumsEarned	85670000000	usd
CY2021	us-gaap	Direct Premiums Earned DirectPremiumsEarned	76320000000	usd
CY2023	us-gaap	Assumed Premiums Earned AssumedPremiumsEarned	350000000	usd
CY2022	us-gaap	Assumed Premiums Earned AssumedPremiumsEarned	432000000	usd
CY2021	us-gaap	Assumed Premiums Earned AssumedPremiumsEarned	492000000	usd
CY2023	us-gaap	Ceded Premiums Earned CededPremiumsEarned	911000000	usd
CY2022	us-gaap	Ceded Premiums Earned CededPremiumsEarned	772000000	usd
CY2021	us-gaap	Ceded Premiums Earned CededPremiumsEarned	680000000	usd
CY2023	us-gaap	Premiums Earned Net PremiumsEarnedNet	99192000000	usd
CY2022	us-gaap	Premiums Earned Net PremiumsEarnedNet	85330000000	usd
CY2021	us-gaap	Premiums Earned Net PremiumsEarnedNet	76132000000	usd
CY2023	us-gaap	Policyholder Benefits And Claims Incurred Gross PolicyholderBenefitsAndClaimsIncurredGross	86738000000	usd
CY2022	us-gaap	Policyholder Benefits And Claims Incurred Gross PolicyholderBenefitsAndClaimsIncurredGross	71357000000	usd
CY2021	us-gaap	Policyholder Benefits And Claims Incurred Gross PolicyholderBenefitsAndClaimsIncurredGross	64339000000	usd
CY2023	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Assumed ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed	223000000	usd
CY2022	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Assumed ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed	379000000	usd
CY2021	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Assumed ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountAssumed	398000000	usd
CY2023	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Ceded ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded	714000000	usd
CY2022	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Ceded ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded	663000000	usd
CY2021	us-gaap	Reinsurance Effect On Claims And Benefits Incurred Amount Ceded ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded	549000000	usd
CY2023	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	86247000000	usd
CY2022	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	71073000000	usd
CY2021	us-gaap	Policyholder Benefits And Claims Incurred Net PolicyholderBenefitsAndClaimsIncurredNet	64188000000	usd
CY2023Q4	us-gaap	Guarantee Obligations Maximum Exposure GuaranteeObligationsMaximumExposure	300000000	usd
CY2023Q4	cvs	Contractual Obligations To Maintain Levels Of Separate Accounts ContractualObligationsToMaintainLevelsOfSeparateAccounts	834000000	usd
CY2022Q4	cvs	Contractual Obligations To Maintain Levels Of Separate Accounts ContractualObligationsToMaintainLevelsOfSeparateAccounts	941000000	usd
CY2023Q4	cvs	Guarantor Obligations Number Of Leases GuarantorObligationsNumberOfLeases	63	lease
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3	segment
CY2022	us-gaap	Revenues Revenues	322467000000	usd
CY2022	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	18037000000	usd
CY2021	us-gaap	Revenues Revenues	292111000000	usd
CY2021	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	17227000000	usd
CY2023	cvs	Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax	356623000000	usd
CY2023	us-gaap	Net Investment Income NetInvestmentIncome	1153000000	usd
CY2023	us-gaap	Revenues Revenues	357776000000	usd
CY2023	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	17534000000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4366000000	usd
CY2022	cvs	Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax	321629000000	usd
CY2022	us-gaap	Net Investment Income NetInvestmentIncome	838000000	usd
CY2022	us-gaap	Revenues Revenues	322467000000	usd
CY2022	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	18037000000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4224000000	usd
CY2021	cvs	Premiums Earned Net And Revenue From Contract With Customer Excluding Assessed Tax PremiumsEarnedNetAndRevenueFromContractWithCustomerExcludingAssessedTax	290912000000	usd
CY2021	us-gaap	Net Investment Income NetInvestmentIncome	1199000000	usd
CY2021	us-gaap	Revenues Revenues	292111000000	usd
CY2021	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	17227000000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4486000000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	13743000000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	7954000000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	13310000000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1905000000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1785000000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2233000000	usd
CY2023	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-497000000	usd
CY2022	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-320000000	usd
CY2021	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	176000000	usd
CY2023	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	487000000	usd
CY2022	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	0	usd
CY2021	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	132000000	usd
CY2023	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	507000000	usd
CY2022	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	0	usd
CY2021	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	0	usd
CY2023	cvs	Office Real Estate Optimization Charges OfficeRealEstateOptimizationCharges	46000000	usd
CY2022	cvs	Office Real Estate Optimization Charges OfficeRealEstateOptimizationCharges	117000000	usd
CY2021	cvs	Office Real Estate Optimization Charges OfficeRealEstateOptimizationCharges	0	usd
CY2023	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	349000000	usd
CY2022	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	2533000000	usd
CY2021	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2023	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	usd
CY2022	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-5803000000	usd
CY2021	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	usd
CY2023	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
CY2022	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	475000000	usd
CY2021	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
CY2023	cvs	Store Impairment Charges StoreImpairmentCharges	0	usd
CY2022	cvs	Store Impairment Charges StoreImpairmentCharges	0	usd
CY2021	cvs	Store Impairment Charges StoreImpairmentCharges	1358000000	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	431000000	usd
CY2023	cvs	Business Combination Purchase Price Adjustment Outside Of Measurement Period BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod	0	usd
CY2022	cvs	Business Combination Purchase Price Adjustment Outside Of Measurement Period BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod	0	usd
CY2021	cvs	Business Combination Purchase Price Adjustment Outside Of Measurement Period BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod	61000000	usd
CY2023	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	17534000000	usd
CY2022	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	18037000000	usd
CY2021	cvs	Adjusted Operating Income Loss AdjustedOperatingIncomeLoss	17227000000	usd
CY2021	cvs	Number Of Stores Planned Closure NumberOfStoresPlannedClosure	900	store
CY2021	cvs	Business Combination Purchase Price Adjustment Outside Of Measurement Period BusinessCombinationPurchasePriceAdjustmentOutsideOfMeasurementPeriod	61000000	usd
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	Boston, Massachusetts
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0000064803-24-000007-index-headers.html	Edgar Link	pending
0000064803-24-000007-index.html	Edgar Link	pending
0000064803-24-000007.txt	Edgar Link	pending
0000064803-24-000007-xbrl.zip	Edgar Link	pending
cvs-20231231.htm	Edgar Link	pending
cvs-20231231.xsd	Edgar Link	pending
cvs-20231231_g1.jpg	Edgar Link	pending
cvs-20231231_g2.jpg	Edgar Link	pending
cvshealthlogo.jpg	Edgar Link	pending
exhibit1022-2023.htm	Edgar Link	pending
exhibit1045-2023.htm	Edgar Link	pending
exhibit1047-2023.htm	Edgar Link	pending
exhibit1053-2023.htm	Edgar Link	pending
exhibit1054-2023.htm	Edgar Link	pending
exhibit211-2023.htm	Edgar Link	pending
exhibit231-2023.htm	Edgar Link	pending
exhibit311-2023.htm	Edgar Link	pending
exhibit312-2023.htm	Edgar Link	pending
exhibit321-2023.htm	Edgar Link	pending
exhibit322-2023.htm	Edgar Link	pending
exhibit429-2023.htm	Edgar Link	pending
exhibit971-2023.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
cvs-20231231_cal.xml	Edgar Link	unprocessable
cvs-20231231_lab.xml	Edgar Link	unprocessable
cvs-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cvs-20231231_htm.xml	Edgar Link	completed
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
R116.htm	Edgar Link	pending
R117.htm	Edgar Link	pending
R118.htm	Edgar Link	pending
R119.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R120.htm	Edgar Link	pending
R121.htm	Edgar Link	pending
R122.htm	Edgar Link	pending
R123.htm	Edgar Link	pending
R124.htm	Edgar Link	pending
R125.htm	Edgar Link	pending
R126.htm	Edgar Link	pending
R127.htm	Edgar Link	pending
R128.htm	Edgar Link	pending
R129.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R130.htm	Edgar Link	pending
R131.htm	Edgar Link	pending
R132.htm	Edgar Link	pending
R133.htm	Edgar Link	pending
R134.htm	Edgar Link	pending
R135.htm	Edgar Link	pending
R136.htm	Edgar Link	pending
R137.htm	Edgar Link	pending
R138.htm	Edgar Link	pending
R139.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R140.htm	Edgar Link	pending
R141.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
cvs-20231231_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CVS
CVS HEALTH Corp Stock $cvs

2024 Q1 Form 10-K Financial Statement

#000006480324000007 Filed on February 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVS CVS HEALTH Corp Stock $cvs

2024 Q1 Form 10-K Financial Statement

#000006480324000007 Filed on February 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVS
CVS HEALTH Corp Stock $cvs